June 2014 Issue of MMM
JUNE 2014 ISSUE
At MM&M's Leadership Exchange, the passion, candor, enthusiasm and respect were second-to-none
Click the above link to access the complete Digital Edition of the June 2014 issue of MM&M, with all text, charts and pictures.
Marketing a diagnostic and drug in tandem requires a new business model. Collaborators Abbott and Pfizer have found success by coordinating marketplace efforts and promoting ...
One year on from the inaugural Healthcare Marketers Trend Report and the industry is continuing its transformation. Our exclusive survey of director-level execs benchmarks the ...
As the industry continues to evolve, so must the agency/client relationship. How can pharma clients and their partners collaborate successfully in the face of mounting ...
Gilead's curative but high-priced hepatitis C pill Sovaldi stirred payer frustration after its launch smashed sales records. Now firms from biotech to big pharma are ...
Mobile is fast becoming the dominant way for people to digest digital information, but the medium presents hurdles for pharma. Ritesh Patel and Ben Currie ...
Yuji Matsue, Chairman and CEO, Americas Region, Eisai
Access to payers is about knowledge, about understanding what they do in their jobs
Months before FDA's expected main venture this summer into regulating medical marketers' activities in social media, the industry reacted sharply to a draft guidance the ...
Cardiologists should be prepared for an amplified push for the BMS/Pfizer blood thinner Eliquis.
Marketing and selling expenses are down, while Olysio sales helped fuel a pharmaceutical sales jump of 7.7% for Johnson & Johnson
News on Merck, Mount Sinal Hospital and Doximity
Med Ed Report
With pollen season approaching its peak, drugmakers are educating doctors on a new class of allergy tablets. It could be a while before they're made ...
While two dozen enforcement letters were sent by FDA's Office of Prescription Drug Promotion to pharma companies last year, up from 21 in 2012, none ...
News on the University of Louisville CME program, Merck, GlobalData and BroadcastMed
The NEJM Group, the organization behind the New England Journal of Medicine and NEJM Journal Watch, has launched a tool that seeks to infuse the ...
The iPad and iPhone resource from Medscape has one purpose: to funnel medical news to a professional's device
News on Symphony Health Solutions, Wolters Kluwer Health and Frontline Medical Communications
Stage 1 of the three stages of meaningful use criteria has ended, and Stage 2 is rolling out. So far, it's unclear if the incentives ...
A recent study of physicians found no correlation between following EHR meaningful use requirements and providing consistently higher quality of care.
Merck's lead digital health strategist and his business partner offer a glimpse of what's possible through pharma and EHR collaborations.
News on Twitter, Olympus and Apple
Two recent consumer campaigns for prescription weight-loss medications show that marketers are seeking to gain mindshare using the same tonality and talking points as non-prescription ...
The BREO campaign works on many levels to be memorable.
Ironwood Pharmaceuticals and Forest Laboratories have launched a campaign to get patients with irritable bowel syndrome with constipation or chronic ideopathic constipation to talk about ...
The pharma market research major is working on unifying into one company with two main product lines, and is also in the process of a ...
ConvergeHEALTH by Deloitte has entered into a multi-year collaboration with Forest Labs and Intermountain Healthcare to conduct outcomes research.
The newly formed group will be known as Calcium with Steve Michaelson, formerly of Rosetta Wishbone, at the helm.
Kane & Finkel, the independent San Francisco-based shop founded in 1997 by John Kane and Bob Finkel, has closed, an executive confirmed.
News on Publicis, Palio+Ignite, PulseCX, McCann HumanCare and GolinHarris
A patient who is diagnosed earlier and receives the most efficacious treatment is the least expensive
A Manhattan Institute analysis says that helping underperforming FDA drug review divisions match the output of high-performing divisions could cut development costs and speed approval ...
Nineteen Republicans on the House Energy and Commerce Committee want FDA commissioner Margaret Hamburg to explain the role the American Association for Justice (trial lawyers) ...
Digital collaboration platforms make it convenient for pharma and thought leaders to engage
The new information age in which we live has made it unnecessary for patients to "live in the dark"
Evan Young, associate creative director, Renavatio Healthcare Communications.
Michael A. Griffith, Executive vice president, inVentiv Health
At Work With
Tom Donnelly, Group Managing Director, Evoke Health
Promotions and hires for manufacturers, agencies and technology companies
We identify not with just the product, but with what it represents
What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.
A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.